Skip to content

Study · Randomized controlled trial · n = 41 · 2013

6 results

Effects of a 10-day oxytocin trial in older adults on health and well-being.

Barraza JA, Grewal NS, Ropacki S, Perez P, Gonzalez A, Zak PJ

Experimental and clinical psychopharmacology18 Feb 2013Cited by 41 (Europe PMC)

PMID23421352 (opens in a new tab)DOI10.1037/a0031581 (opens in a new tab)PepBankPUB-23421352
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In older adults living in residences, 10 days of intranasal oxytocin produced no change in mood.

    In plain wordsIn older adults, 10 days of oxytocin through the nose did not change mood.

    Peptide
    Oxytocin
    Outcome
    No significant changeMood
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    No changes in mood or cardiovascular states were observed across the 10-day period.
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In older adults living in residences, 10 days of intranasal oxytocin produced no change in cardiovascular states.

    In plain wordsIn older adults, 10 days of oxytocin through the nose did not change heart and blood vessel measures.

    Peptide
    Oxytocin
    Outcome
    No significant changeCardiovascular states
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    No changes in mood or cardiovascular states were observed across the 10-day period.
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In older adults, dispositional gratitude improved with oxytocin, although it declined in placebo controls over the 10 days.

    In plain wordsIn older adults, gratitude rose with oxytocin through the nose, while it fell with placebo over 10 days.

    Peptide
    Oxytocin
    Outcome
    IncreaseDispositional gratitude
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Repeated-measures ANOVAs showed that dispositional gratitude improved for the OT infused participants, although gratitude declined for placebo controls over the 10 days (p = .015).
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In older adults, those given oxytocin did not report the decline in physical functioning that occurred in the placebo condition.

    In plain wordsIn older adults, those given oxytocin did not report a drop in physical functioning, but the placebo group did.

    Peptide
    Oxytocin
    Outcome
    IncreasePhysical functioning
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Those in the OT condition did not report a decline in physical functioning over time as was observed in the placebo condition (p = .05)
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In older adults, those given oxytocin reported less fatigue than controls.

    In plain wordsIn older adults, those given oxytocin through the nose reported less fatigue than those given placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseFatigue
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    and also reported less fatigue compared with controls (p = .03).
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.
  6. 06HumanRandomized controlled trialSafety outcome

    In older adults, no significant adverse events were reported during 10 days of intranasal oxytocin.

    In plain wordsIn older adults, no significant side effects were reported during 10 days of oxytocin through the nose.

    Peptide
    Oxytocin
    Outcome
    No significant changeAdverse events
    Study

    n = 41

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    40 IU · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    No significant adverse events were reported throughout the entirety of the study, indicating that OT can be safely used with older adults.
    2 context sentences
    Summary · context
    Residentially housed older adults (N = 41, mean age of 80) were enrolled in a randomized, double-blind, placebo-controlled study.
    Summary · context
    Participants received 40 IU intranasal OT or placebo for 10 consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.